Regeneron named to Dow Jones Best-in-Class World Index for seventh straight year

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • Regeneron named to Dow Jones Best-in-Class World Index for seventh straight year, one of eight biotechnology companies included globally.
  • Also kept place on Dow Jones Best-in-Class North America Index for sixth consecutive year, one of four U.S.-based biotechnology firms recognized.
  • Announcement flagged new 2030 science-led responsibility goals, alongside publication of 2025 Responsibility Report showing it met or exceeded nearly all 2025 targets.
  • Update also pointed to recent decision to provide its new gene therapy for a specific form of congenital hearing loss for free in the United States, citing patient-access focus.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080700PRIMZONEFULLFEED9716195) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.